Future of cancer vaccines

Methods in Molecular Biology

Volumn 1139, Issue , 2014, Pages 555-564

  Winter, Hauke ^a   Fox, Bernard A ^b,c,d   Rüttinger, Dominik ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b EARLE A CHILES RESEARCH INSTITUTE   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Biomarkers; Cancer vaccines; Clinical trial; Future perspective; Immunotherapy

Indexed keywords

BIOLOGICAL MARKER; CANCER VACCINE; SIPULEUCEL T; TISSUE EXTRACT; TUMOR MARKER;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; HEALTH CARE QUALITY; HUMAN; IMMUNE RESPONSE; MULTIMODALITY CANCER THERAPY; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); STUDY DESIGN; TREATMENT RESPONSE; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; NEOPLASM; REVIEW;

CANCER VACCINES; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; NEOPLASMS; TISSUE EXTRACTS; TUMOR MARKERS, BIOLOGICAL;

EID: 84908290484     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-0345-0_40     Document Type: Article

References (21)

1. Kantoff PW et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363: 411-422.
2. Higano CS et al (2009) Integrated data from 2 randomized, double-blind, placebo-controlled phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 115: 3670-3679.
3. Stein WD et al (2011) Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. Clin Cancer Res 17: 907-917.
4. Wolchok JD et al (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15: 7412-7420.
5. Hoos A et al (2010) Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 102: 1388-1397.
6. Guidance for industry: Clinical considerations for therapeutic cancer vaccines (2011) US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. http://www. fda. gov/biologicsbloodvaccines/guidancecomplianceregulatoryinformation.
7. Schuster SJ et al (2011) Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol 29: 2787-2794.
8. Schwartzentruber DJ et al (2011) Gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 364: 2119-2127.
9. Sosman JA et al (2008) Three phase II cytokine working group trials of gp100 (210 M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma. J Clin Oncol 26: 2292-2298.
10. Rosenberg SA et al (1998) Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg 228: 307-319.
11. Tyagi P, Mirakhur B (2009) MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy. Clin Lung Cancer 10: 371-374.
12. Hodge JW et al (2012) The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors. Semin Oncol 39: 323-339.
13. Ferrer IR et al (2011) Paradoxical aspects of rapamycin immunobiology in transplantation. Am J Transplant 11: 654-659.
14. Laheru D et al (2008) Allogeneic granulocyte macrophage colony-stimulating factorsecreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin Cancer Res 14: 1455-1463.
15. Walter S et al (2012) Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 18(8): 1254-1261.
16. Disis ML (2011) Immunologic biomarkers as correlates of clinical response to cancer immunotherapy. Cancer Immunol Immunother 60: 433-442.
17. Gajewski TF et al (2010) Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy. Cancer J 16: 399-403.
18. Mlecnik B et al (2011) Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 29: 610-618.
19. Fridman WH et al (2012) The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12: 298-306.
20. Butterfield LH et al (2011) Recommendations from the iSBTc-SITC/FDA/NCI workshop on immunotherapy biomarkers. Clin Cancer Res 17: 3064-3076.
21. Galon J et al (2012) The immune score as a new possible approach for the classification of cancer. J Transl Med 10: 1.